Press Release – February 1, 2021
CellR4 indexed in DOAJ
We are glad to announce that CellR4 has just been indexed in the Directory of Open Access Journals (DOAJ) thanks to the remarkable improvements that have been made in the journal’s quality over the last few years. DOAJ is a well-known community-curated online directory that indexes and provides access to high quality, open access, peer-reviewed journals (https://doaj.org/).
Press Release – January 5, 2021
Groundbreaking trial sheds light on the safety and effectiveness of umbilical cord-derived mesenchymal stem cells for COVID-19 treatment
Prof. Camillo Ricordi and other researchers affiliated with University of Miami Miller School of Medicine and The Cure Alliance led a groundbreaking phase 1/2a, randomized controlled trial showing that umbilical cord-derived mesenchymal stem cell (MSC) infusions safely reduce risk of death and quicken time to recovery for patients with severe COVID-19, according to results published in STEM CELLS Translational Medicine in January 2021. The protocol of this trial was previously published in CellR4 in April 2020: Lanzoni et al., Umbilical cord-derived mesenchymal stem cells for COVID-19 patients with acute respiratory distress syndrome (ARDS). CellR4 2020; 8: e2839. DOI: 10.32113/cellr4_20204_2839.
Press Release – January 7, 2020
A New Managing Editor for CellR4
CellR4 was launched in 2013 by Prof. Camillo Ricordi (Founder of The Cure Alliance) with the aim of providing a platform for discussion of challenges and opportunities in the development of new treatments, independent from the disease target (a unique feature of top-class medical journals). CellR4 was created with true Open Access character, the full text of articles being downloaded free of charge by readers.
The Editor-in-Chief Prof. Camillo Ricordi has now asked the experienced researcher Dr. Marco Infante to join him in the next phase of CellR4 development as the new Managing Editor of our journal.
CellR4 will continue to focus on cellular events in the study and treatment of disease, with the emphasis on cellular repair, replacement, regeneration and reprogramming. Papers dealing with all types of disease or conditions – irrespective of cause, organ system or classification – are welcome, with an emphasis on translational aspects concerning areas of unmet clinical needs and diseases so far considered as incurable. Dr. Infante is actively encouraging high-level opinion and perspectives papers as well as those that cover original research and/or clinical methods.